Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Travere Therapeutics, Inc. (RTRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 SC 13G/A BlackRock Inc. reports a 10.3% stake in Travere Therapeutics, Inc.
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/03/2023 8-K Quarterly results
Docs: "Travere Therapeutics Reports Second Quarter 2023 Financial Results"
07/17/2023 8-K Quarterly results
05/31/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
05/15/2023 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in TRAVERE THERAPEUTICS, INC.
05/10/2023 144 Form 144 - Report of proposed sale of securities:
05/10/2023 144 Form 144 - Report of proposed sale of securities:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
Docs: "Travere Therapeutics Reports First Quarter 2023 Financial Results FILSPARI™ granted accelerated approval by FDA for the reduction of proteinuria in IgA nephropathy on February 17th, 2023&#59; commercial launch underway"
05/01/2023 8-K Quarterly results
04/13/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/13/2023 SC 13G ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 5.9% stake in Travere Therapeutics, Inc.
03/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and among Travere Therapeutics, Inc., Jefferies LLC, J.P. Morgan Securities LLC, BofA Securities, Inc. and SVB Securities LLC",
"Form of Pre-Funded Warrant",
"Opinion of Cooley LLP",
"Travere Therapeutics Announces Proposed Public Offering of Common Stock",
"Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants"
03/01/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/27/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 6.2% stake in TRAVERE THERAPEUTICS, INC.
02/14/2023 SC 13G/A MACQUARIE GROUP LTD reports a 5.5% stake in Travere Therapeutics, Inc.
02/14/2023 SC 13G/A ARMISTICE CAPITAL, LLC reports a 10% stake in TRAVERE THERAPEUTICS, INC.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 5.5% stake in Travere Therapeutics Inc.
02/09/2023 SC 13G/A ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 4% stake in Travere Therapeutics, Inc.
02/06/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Travere Therapeutics Provides Corporate Update and 2023 Outlook"
10/28/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
10/27/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/27/2022 8-K Quarterly results
10/13/2022 8-K Other Events  Interactive Data
08/22/2022 8-K Quarterly results
08/18/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy